Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
DAN-222
i
Other names:
DAN-222, camptothecin conjugated polymeric nanoparticle
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(2)
News
Trials
Company:
Dantari
Drug class:
Topoisomerase I inhibitor
Related drugs:
‹
fam-trastuzumab deruxtecan-nxki (90)
irinotecan (48)
U3-1402 (28)
sacituzumab govitecan-hziy (17)
topotecan (16)
SHR-A1811 (15)
datopotamab deruxtecan (11)
DM001 (6)
DS-7300 (5)
AZD8205 (5)
AMB302 (4)
DB-1310 (4)
DM002 (4)
BNT323 (4)
BL-M07D1 (3)
DS-6157 (3)
HRA00129-C004 (3)
sacituzumab tirumotecan (3)
nanoliposomal irinotecan (3)
PLX038 (3)
ABBV-400 (3)
CUSP06 (2)
DM005 (2)
PRO1102 (2)
SSH20 (2)
IMMU-130 (2)
AZD9592 (2)
AMT-562 (1)
BAT8008 (1)
BL-M02D1 (1)
BNT324 (1)
camptothecin nanosomal (1)
DAN-311 (1)
ELU001 (1)
HMBD-501 (1)
IMMU-140 (1)
IT-141 (1)
OBI-992 (1)
OQY-3258 (1)
PF-08046044 (1)
rinatabart sesutecan (1)
SGN-CD30C (1)
SHR-A2102 (1)
STRO-003 (1)
ZW191 (1)
ZW220 (1)
ZW251 (1)
IBI-343 (1)
BL-B01D1 (1)
AZD5335 (1)
ABBV-706 (0)
ARC-401 (0)
BAT8007 (0)
BAT8010 (0)
BL-M11D1 (0)
BNT326 (0)
CEB-01 (0)
CPO301 (0)
belotecan (0)
DS-3939 (0)
FZ-AD004 (0)
GEN1160 (0)
GSK5733584 (0)
GSK5764227 (0)
HA-irinotecan (0)
HLX43 (0)
IBI-130 (0)
IBI-354 (0)
ICAM‑1 ADC (0)
LMP744 (0)
LY4170156 (0)
lentinan (0)
TLC388 (0)
MHB036C (0)
MHB088C (0)
NK012 (0)
etirinotecan pegol (0)
SHR-A1912 (0)
SKB315 (0)
TQB2102 (0)
TQB2103 (0)
VIP236 (0)
YL201 (0)
CBX-12 (0)
JSKN003 (0)
EP0057 (0)
SHR-A1904 (0)
LMP400 (0)
HR070803 (0)
irinotecan liposomal (0)
LY01616 (0)
FF-10850 (0)
PEN-866 (0)
SSS22 (0)
M9140 (0)
DS-6000 (0)
SHR-A2009 (0)
simmitecan (0)
SHR-A1921 (0)
topotecan episcleral (0)
fam-trastuzumab deruxtecan-nxki (90)
irinotecan (48)
U3-1402 (28)
sacituzumab govitecan-hziy (17)
topotecan (16)
SHR-A1811 (15)
datopotamab deruxtecan (11)
DM001 (6)
DS-7300 (5)
AZD8205 (5)
AMB302 (4)
DB-1310 (4)
DM002 (4)
BNT323 (4)
BL-M07D1 (3)
DS-6157 (3)
HRA00129-C004 (3)
sacituzumab tirumotecan (3)
nanoliposomal irinotecan (3)
PLX038 (3)
ABBV-400 (3)
CUSP06 (2)
DM005 (2)
PRO1102 (2)
SSH20 (2)
IMMU-130 (2)
AZD9592 (2)
AMT-562 (1)
BAT8008 (1)
BL-M02D1 (1)
BNT324 (1)
camptothecin nanosomal (1)
DAN-311 (1)
ELU001 (1)
HMBD-501 (1)
IMMU-140 (1)
IT-141 (1)
OBI-992 (1)
OQY-3258 (1)
PF-08046044 (1)
rinatabart sesutecan (1)
SGN-CD30C (1)
SHR-A2102 (1)
STRO-003 (1)
ZW191 (1)
ZW220 (1)
ZW251 (1)
IBI-343 (1)
BL-B01D1 (1)
AZD5335 (1)
ABBV-706 (0)
ARC-401 (0)
BAT8007 (0)
BAT8010 (0)
BL-M11D1 (0)
BNT326 (0)
CEB-01 (0)
CPO301 (0)
belotecan (0)
DS-3939 (0)
FZ-AD004 (0)
GEN1160 (0)
GSK5733584 (0)
GSK5764227 (0)
HA-irinotecan (0)
HLX43 (0)
IBI-130 (0)
IBI-354 (0)
ICAM‑1 ADC (0)
LMP744 (0)
LY4170156 (0)
lentinan (0)
TLC388 (0)
MHB036C (0)
MHB088C (0)
NK012 (0)
etirinotecan pegol (0)
SHR-A1912 (0)
SKB315 (0)
TQB2102 (0)
TQB2103 (0)
VIP236 (0)
YL201 (0)
CBX-12 (0)
JSKN003 (0)
EP0057 (0)
SHR-A1904 (0)
LMP400 (0)
HR070803 (0)
irinotecan liposomal (0)
LY01616 (0)
FF-10850 (0)
PEN-866 (0)
SSS22 (0)
M9140 (0)
DS-6000 (0)
SHR-A2009 (0)
simmitecan (0)
SHR-A1921 (0)
topotecan episcleral (0)
›
Associations
(2)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY 2) (NCT01042379)
Phase 2
QuantumLeap Healthcare Collaborative
QuantumLeap Healthcare Collaborative
Recruiting
Phase 2
QuantumLeap Healthcare Collaborative
Recruiting
Last update posted :
10/22/2024
Initiation :
03/01/2010
Primary completion :
12/01/2030
Completion :
12/01/2031
HER-2 • ER
|
ER positive • ER negative
|
Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1
A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer (NCT05261269)
Phase 1
Dantari, Inc.
Dantari, Inc.
Completed
Phase 1
Dantari, Inc.
Completed
Last update posted :
12/13/2023
Initiation :
02/02/2022
Primary completion :
09/13/2023
Completion :
10/11/2023
HER-2
|
HER-2 positive • HER-2 negative
|
Zejula (niraparib) • DAN-222
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login